Αρχική σελίδα » Κέντρο Εμπειρογνωμοσύνης » Αυτοφλεγμονώδη:«Αυτοάνοσα Νοσήματα του Συνδετικού Ιστού και Μυοσκελετικών Παθήσεων» ERN – RECONET » Δημοσιεύσεις

Δημοσιεύσεις

  1. Lymphomagenesis in Sjögren's syndrome: Predictive biomarkers towards precision medic, Autoimmun 2019, Feb;18(2):137-143, Goules AV, Tzioufas AG,  doi:10.1016/j.autrev.2018.08.007, Epub 2018 Dec 17. Review, PMID: 30572133
  2. Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies, Clin Rheumatol, 2019, Jan;38(1):125-132, Zampeli E, Venetsanopoulou A, Argyropoulou OD, Mavragani CP, Tektonidou MG, Vlachoyiannopoulos PG, Tzioufas AG, Skopouli FN, Moutsopoulos HM, doi: 10.1007/s10067-018-4267-z., Epub 2018 Aug 25, PMID: 30145635
  3. TNFAIP3 F127C Coding Variation in Greek Primary Sjogren's Syndrome Patients, J Immunol Res, 2018, Dec 19;2018:6923213, Nezos A, Gkioka E, Koutsilieris M, Voulgarelis M, Tzioufas AG, Mavragani CP., doi: 10.1155/2018/6923213, eCollection 2018, PMID: 30662920
  4. Analysis of NLRP3, MVK and TNFRSF1A variants in adult Greek patients with autoinflammatory symptoms, Clin Exp Rheumatol, 2018, Nov-Dec;36(6 Suppl 115):86-89, Karagianni P, Nezos A, Ioakeim F, Tzioufas AG, Moutsopoulos HM, Epub 2018 Nov 9, PMID: 30418111
  5. Severe cutaneous hand infection: Mycobacterium marinum in an immunosuppressed patient, Clin Exp Rheumatol, 2018, Nov-Dec;36(6):1117, Argyropoulou OD, Zampeli E, Sipsas NV, Tzioufas AG, Moutsopoulos HM, Epub 2018 Jul 19. No abstract available
  6. PMID:How can autoantibodies predict the long-term outcome of patients with interstitial lung disease? Results from a retrospective cohort study, Autoimmun Rev., 2018, Nov;17(11):1124-1133, Kampolis CF, Venetsanopoulou AI, Karakontaki F, Polychronopoulos V, Vlachoyiannopoulos P, Tzioufas AG, doi: 10.1016/j.autrev.2018.06.004. Epub 2018 Sep 11, PMID:30213691
  7. Cryoglobulinaemia, Nat Rev Dis Primers, 2018, Aug 2;4(1):11, Roccatello D, Saadoun D, Ramos-Casals M, Tzioufas AG, Fervenza FC, Cacoub P, Zignego AL, Ferri C,    doi: 10.1038/s41572-018-0009-4, Review, PMID: 30072738
  8. Low miR200b-5p levels in minor salivary glands: a novel molecular marker predicting lymphoma development in patients with Sjögren's syndrome, Ann Rheum Dis, 2018, Aug;77(8):1200-1207, Kapsogeorgou EK, Papageorgiou A, Protogerou AD, Voulgarelis M, Tzioufas AG, doi: 10.1136/annrheumdis-2017-212639, Epub 2018 May 19, PMID:29779010
  9. Decrease in the ratio of polyreactive IgG titers with IgG concentration is associated with long-term complications of primary Sjögren's syndrome, Clin Exp Rheumatol, 2018, May-Jun;36 Suppl 112(3):239-240, Argyropoulou OD, Gunti S, Kapsogeorgou EK, Notkins AL, Tzioufas AG, Epub 2018 Aug 14, No abstract available, PMID:30156547
  10. Cohort Harmonization and Integrative Analysis from a Biomedical Engineering Perspective, IEEE Rev Biomed Eng, 2018, Jul 11, Kourou K, Pezoulas VC, Georga EI, Exarchos T, Tsanakas P, Tsiknakis M, Varvarigou T, De Vita S, Tzioufas A, Fotiadis DII, doi:10.1109/RBME.2018.2855055, [Epub ahead of print], PMID:30004887
  11. Towards the Establishment of a Biomedical Ontology for the Primary Sjögren's Syndrome, Conf Proc IEEE Eng Med Biol Soc, 2018, Jul;2018:4089-4092, Pezoulas VC, Exarchos TP, Andronikou V, Varvarigou T, Tzioufas AG, De Vita S, Fotiadis DI, doi:10.1109/EMBC.2018.8513349, PMID: 30441255
  12. Limited efficacy of targeted treatments in Sjögren's syndrome: why?, Clin Exp Rheumatol, 2018, May-Jun;36 Suppl 112(3):27-28, Tzioufas AG, Goules AV, Epub 2018 Jun 21, No abstract available, PMID: 29998826
  13. Central nervous system involvement in patients with granulomatosis with polyangiitis: a single-center retrospective study, Clin Rheumatol, 2018, Mar;37(3):737-747, Fragoulis GE, Lionaki S, Venetsanopoulou A, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzioufas AG, doi: 10.1007/s10067-017-3835-y, Epub 2017 Sep 15, PMID: 28914375
  14. Non-invasive vascular biomarkers in patients with Behçet's disease: review of the data and future perspectives, Clin Exp Rheumatol, 2017,               Nov-Dec;35 Suppl 108(6):100-107, Protogerou AD, Nasothimiou EG, Sfikakis PP, Tzioufas AG, Epub 2017 Oct 6, Review, PMID: 29148423
  15. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece, Rheumatol Int, 2017, Sep;37(9):1441-1452,Tzanetakos C, Tzioufas A, Goules A, Kourlaba G, Theodoratou T, Christou P, Maniadakis N, doi: 10.1007/s00296-017-3736-z, Epub 2017 May 18, PMID: 28523420
  16. Insight into pathogenesis of Sjögren's syndrome: Dissection on autoimmune infiltrates and epithelial cells, Clin Immunol, 2017, Sep;182:30-40, Goules AV, Kapsogeorgou EK, Tzioufas AG, doi: 10.1016/j.clim.2017.03.007, Epub 2017 Mar 19, Review, PMID: 28330683
  17. MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome, Sci Rep, 2017, Aug 4;7(1):7354, Fragkioudaki S, Nezos A, Souliotis VL, Chatziandreou I, Saetta AA, Drakoulis N, Tzioufas AG, Voulgarelis M, Sfikakis PP, Koutsilieris M, Crow MK, Moutsopoulos HM, Mavragani CP, doi:10.1038/s41598-017-07347-w, PMID: 28779180
  18. Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjögren's syndrome, Clin Exp Rheumatol, 2017, Jul-Aug;35(4):719-720, Quartuccio L, Mavragani CP, Nezos A, Gandolfo S, Tzioufas AG, De Vita S, Epub 2017 Mar 8. No abstract available, PMID: 28281461
  19. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database, Clin Exp Rheumatol, 2017, Jul-Aug;35(4):579-585, Sfikakis PP, Bournia VK, Sidiropoulos P, Boumpas DT, Drosos AA, Kitas GD, Konstantonis G, Liossis SN, Manoussakis MN, Sakkas L, Tektonidou M, Tzioufas AG, Vlachoyiannopoulos PG, Kani C, Paterakis P, Litsa P, Vassilopoulos D, Epub 2017 Mar 3, PMID: 28281458
  20. Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome, Ann Rheum Dis, 2017, Jul;76(7):1161-1168, Fisher BA, Jonsson R, Daniels T, Bombardieri M, Brown RM, Morgan P, Bombardieri S, Ng WF, Tzioufas AG, Vitali C, Shirlaw P, Haacke E, Costa S, Bootsma H, Devauchelle-Pensec V, Radstake TR, Mariette X, Richards A, Stack R, Bowman SJ, Barone F; Sjögren's histopathology workshop group (appendix) from ESSENTIAL (EULAR Sjögren's syndrome study group), doi: 10.1136/annrheumdis-2016-210448, Epub 2016 Dec 13, PMID: 27965259
  21. Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations, Expert Rev Clin Immunol, 2016, 2016;12(2):137-56, Brito-Zerón P, Theander E, Baldini C, Seror R, Retamozo S, Quartuccio L, Bootsma H, Bowman SJ, Dörner T, Gottenberg JE, Mariette X, Bombardieri S, de Vita S, Mandl T, Ng WF, Kruize AA, Tzioufas A, Vitali C, Buyon J, Izmirly P, Fox R, Ramos-Casals M; Eular Sjögren Syndrome Task Force, doi:10.1586/1744666X.2016.1109449, Epub 2015 Dec 22, Review, Erratum in: Expert Rev Clin Immunol, 2017 May;13(5):507, PMID: 26691952
  22. Cell-specific epigenome-wide DNA methylation profile in long-term cultured minor salivary gland epithelial cells from patients with Sjögren's syndrome, Ann Rheum Dis, 2017, Mar;76(3):625-628, Charras A, Konsta OD, Le Dantec C, Bagacean C, Kapsogeorgou EK, Tzioufas AG, Pers JO, Bordron A, Renaudineau Y, doi: 10.1136/annrheumdis-2016-210167, Epub 2017 Jan 16, PMID: 28093418
  23. Primary Sjögren's syndrome: clinical phenotypes, outcome and the development of biomarkers, Immunol Res, 2017, Feb;65(1):331-344, Goules AV, Tzioufas AG, doi: 10.1007/s12026-016-8844-4. Review, PMID: 27444892
  24. Increased frequency of the PTPN22W* variant in primary Sjogren's Syndrome: Association with low type I IFN scores, Clin Immunol, 2016, Dec;173:157-160, Vlachogiannis NI, Nezos A, Tzioufas AG, Koutsilieris M, Moutsopoulos HM, Mavragani CP, doi: 10.1016/j.clim.2016.10.015, Epub 2016 Nov 1, PMID: 27810512
  25. Expression of type III interferons (IFNλs) and their receptor in Sjögren's syndrome, Clin Exp Immunol, 2016, Dec;186(3):304-312, Apostolou E, Kapsogeorgou EK, Konsta OD, Giotakis I, Saridaki MI, Andreakos E, Tzioufas AG, doi: 10.1111/cei.12865, Epub 2016 Oct 4, PMID: 27613139
  26. Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies, Ann Rheum Dis, 2016, Nov;75(11):1945-1950, Seror R, Meiners P, Baron G, Bootsma H, Bowman SJ, Vitali C, Gottenberg JE, Theander E, Tzioufas A, De Vita S, Ramos-Casals M, Dörner T, Quartuccio L, Ravaud P, Mariette X; EULAR Sjögren Task Force, doi:10.1136/annrheumdis-2015-208504, Epub 2016 Jan 25, PMID: 27150113
  27. Clinical and financial burden of active lupus in Greece: a nationwide study, Lupus, 2016, Oct;25(12):1385-94, Bertsias G, Karampli E, Sidiropoulos P, Gergianaki I, Drosos A, Sakkas L, Garyfallos A, Tzioufas A, Vassilopoulos D, Tsalapaki C, Sfikakis P, Panopoulos S, Athanasakis K, Perna A, Psomali D, Kyriopoulos J, Boumpas D, doi:10.1177/0961203316642310Epub 2016 Apr 6, PMID:27055520
  28. Epileptic syndrome in systemic lupus erythematosus and neuronal autoantibody associations, Lupus, 2016, Oct;25(11):1260-5, Kampylafka EI, Alexopoulos H, Fouka P, Moutsopoulos HM, Dalakas MC, Tzioufas AG, doi:10.1177/0961203316636473, Epub 2016 Feb 27, PMID: 26923281
  29. Autoantibodies in Autoimmune Diseases: Clinical and Critical Evaluation, Isr Med Assoc J, 2016, Sep;18(9):519-524, Kapsogeorgou EK, Tzioufas AG, Review, PMID: 28471596
  30. Sjögren syndrome, Nat Rev Dis Primers, 2016, Jul 7;2:16047, Brito-Zerón P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, Sivils K, Theander E, Tzioufas A, Ramos-Casals M, doi: 10.1038/nrdp.2016.47, Review, PMID: 27383445
  31. Primary Sjӧgren's syndrome: Clinical phenotypes, outcome and the development of biomarkers, Autoimmun, 2016, Rev.2016Jul;15(7):695-703, Goules AV, Tzioufas AG, doi:10.1016/j.autrev.2016.03.004, Epub 2016 Mar 9, Review, PMID: 26970487
  32. Epigenetic modifications in salivary glands from patients with Sjögren's syndrome affect cytokeratin 19 expression, Bull Group Int Rech Sci Stomatol Odontol, 2016, Jun 28;53(1):e01, Konsta OD, Charras A, Le Dantec C, Kapsogeorgeou E, Bordron A, Brooks WH, Tzioufas AG, Pers JO, Renaudineau Y, PMID: 27352422
  33. Is salivary gland ultrasonography a useful tool in Sjögren's syndrome? A systematic review, Rheumatology (Oxford), 2016, May;55(5):789-800, Jousse-Joulin S, Milic V, Jonsson MV, Plagou A, Theander E, Luciano N, Rachele P, Baldini C, Bootsma H, Vissink A, Hocevar A, De Vita S, Tzioufas AG, Alavi Z, Bowman SJ, Devauchelle-Pensec V; US-pSS Study Group, doi:10.1093/rheumatology/kev385. Epub 2015 Dec 14, PMID: 26667216
  34. Defective DNA methylation in salivary gland epithelial acini from patients with Sjögren's syndrome is associated with SSB gene expression, anti-SSB/LA detection, and lymphocyte infiltration, J Autoimmun, 2016, Apr;68:30-8, Konsta OD, Le Dantec C, Charras A, Cornec D, Kapsogeorgou EK, Tzioufas AG, Pers JO, Renaudineau Y,      doi: 10.1016/j.jaut.2015.12.002, Epub 2015 Dec 22, PMID: 26725749
  35. Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis, Clin Immunol, 2016, Mar;164:114-8, Vadasz Z, Goldeberg Y, Halasz K, Rosner I, Valesini G, Conti F, Perricone C, Sthoeger Z, Bezalel SR, Tzioufas AG, Levin NA, Shoenfeld Y, Toubi E, doi: 10.1016/j.clim.2016.02.004, Epub 2016 Feb 13, PMID: 26883681
  36. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI), Ann Rheum Dis, 2016, Feb;75(2):382-9, Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, Baron G, Le Guern V, Devauchelle-Pensec V, Ramos-Casals M, Valim V, Dörner T, Tzioufas A, Gottenberg JE, Solans Laqué R, Mandl T, Hachulla E, Sivils KL, Ng WF, Fauchais AL, Bombardieri S, Priori R, Bartoloni E, Goeb V, Praprotnik S, Sumida T, Nishiyama S, Caporali R, Kruize AA, Vollenweider C, Ravaud P, Meiners P, Brito-Zerón P, Vitali C, Mariette X; EULAR Sjögren's Task Force, doi: 10.1136/annrheumdis-2014-206008. Epub 2014 Dec 5, PMID: 25480887
  37. Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements, Rheumatology (Oxford), 2015, Dec;54(12):2230-8, Ramos-Casals M, Brito-Zerón P, Seror R, Bootsma H, Bowman SJ, Dörner T, Gottenberg JE, Mariette X, Theander E, Bombardieri S, De Vita S, Mandl T, Ng WF, Kruize A, Tzioufas A, Vitali C; EULAR Sjögren Syndrome Task Force, doi:10.1093/rheumatology/kev200, Epub 2015 Jul 31. Erratum in: Rheumatology (Oxford), 2017 Jul 1;56(7):1245, PMID: 26231345
  38. Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease, J Neuroimmunol, 2015, Dec 15;289:8-11, Alexopoulos H, Kampylafka EI, Fouka P, Tatouli I, Akrivou S, Politis PK, Moutsopoulos HM, Tzioufas AG, Dalakas MC, doi:10.1016/j.jneuroim.2015.10.007, Epub 2015 Oct 13, PMID: 26616866
  39. Treatment of rheumatoid arthritis: Unraveling the conundrum, J Autoimmun, 2015, Dec;65:1-18, Zampeli E, Vlachoyiannopoulos PG, Tzioufas AG,        doi: 10.1016/j.jaut.2015.10.003. Epub 2015 Oct 27, Review, PMID:26515757
  40. Polyreactive antibodies in the circulation of patients with systemic lupus erythematosus, Lupus, 2015, Dec;24(14):1567-9, Gunti S, Kampylafka EI, Tzioufas AG, Notkins AL, doi:10.1177/0961203315603144Epub 2015 Sep 18, No abstract available, PMID: 26385217
  41. Elevated expression of platelet-derived chemokines in patients with antiphospholipid syndrome. J Autoimmun, 2015, Dec;65:30-7, Patsouras MD, Sikara MP, Grika EP, Moutsopoulos HM, Tzioufas AG, Vlachoyiannopoulos PG, doi: 10.1016/j.jaut.2015.08.001, Epub 2015 Aug 15, PMID: 26283469
  42. Study of microRNAs (miRNAs) that are predicted to target the autoantigens Ro/SSA and La/SSB in primary Sjögren's Syndrome, Clin Exp Immunol, 2015, Oct;182(1):14-22, Gourzi VC, Kapsogeorgou EK, Kyriakidis NC, Tzioufas AG, doi: 10.1111/cei.12664, Epub 2015 Jul 21, PMID: 26201309
  43. A BAFF receptor His159Tyr mutation in Sjögren's syndrome-related lymphoproliferation, Arthritis Rheumatol, 2015, Oct;67(10):2732-41, Papageorgiou A, Mavragani CP, Nezos A, Zintzaras E, Quartuccio L, De Vita S, Koutsilieris M, Tzioufas AG, Moutsopoulos HM, Voulgarelis M, doi: 10.1002/art.39231, PMID: 26097183
  44. Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4, Autoimmunity,     2015, 2015;48(7):453-9, Kampylafka EI, Alexopoulos H, El Hamidieh A, Dalakas MC, Andreakos E, Tzioufas AG, doi:10.3109/08916934.2015.1070836, Epub 2015 Aug 14, PMID: 26287441
  45. Clinical picture, outcome and predictive factors of lymphoma in Sjӧgren syndrome, Autoimmun Rev, 2015, Jul;14(7):641-9, Papageorgiou A, Voulgarelis M, Tzioufas AG., doi:10.1016/j.autrev.2015.03.004, Epub 2015 Mar 22, Review, PMID: 25808075
  46. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI), Ann Rheum Dis, 2015, May;74(5):859-66, Seror R, Theander E, Brun JG, Ramos-Casals M, Valim V, Dörner T, Bootsma H, Tzioufas A, Solans-Laqué R, Mandl T, Gottenberg JE, Hachulla E, Sivils KL, Ng WF, Fauchais AL, Bombardieri S, Valesini G, Bartoloni E, Saraux A, Tomsic M, Sumida T, Nishiyama S, Caporali R, Kruize AA, Vollenweider C, Ravaud P, Vitali C, Mariette X, Bowman SJ; EULAR Sjögren's Task Force, doi: 10.1136/annrheumdis-2013-204615, Epub 2014 Jan 17, PMID: 24442883
  47. Clinical and laboratory predictors of distinct histopathogical features of lupus nephritis, Medicine (Baltimore), 2015, May;94(21):e829, Mavragani CP, Fragoulis GE, Somarakis G, Drosos A, Tzioufas AG, Moutsopoulos HM, doi:10.1097/MD.0000000000000829, PMID: 26020385
  48. Biomarkers. Saliva proteomics is a promising tool to study Sjögren syndrome, Nat Rev Rheumatol, 2015, Apr;11(4):202-3, Tzioufas AG, Kapsogeorgou EK, doi: 10.1038/nrrheum.2015.10, Epub 2015 Feb 10, PMID:  25668140
  49. Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study, Clin Exp Rheumatol, 2015, Mar-Apr;33(2):216-24, Lampropoulos CE, Orfanos P, Bournia VK, Karatsourakis T, Mavragani C, Pikazis D, Manoussakis MN, Tzioufas AG, Moutsopoulos HM, Vlachoyiannopoulos PG, Epub 2015 Feb 9, PMID: 25664400
  50. EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide, RMD Open, 2015, Feb 20;1(1):e000022, Seror R, Bowman SJ, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A, Gottenberg JE, Ramos-Casals M, Dörner T, Ravaud P, Vitali C, Mariette X, Asmussen K, Jacobsen S, Bartoloni E, Gerli R, Bijlsma JW, Kruize AA, Bombardieri S, Bookman A, Kallenberg C, Meiners P, Brun JG, Jonsson R, Caporali R, Carsons S, De Vita S, Del Papa N, Devauchelle V, Saraux A, Fauchais AL, Sibilia J, Hachulla E, Illei G, Isenberg D, Jones A, Manoussakis M, Mandl T, Jacobsson L, Demoulins F, Montecucco C, Ng WF, Nishiyama S, Omdal R, Parke A, Praprotnik S, Tomsic M, Price E, Scofield H, L Sivils K, Smolen J, Laqué RS, Steinfeld S, Sutcliffe N, Sumida T, Valesini G, Valim V, Vivino FB, Vollenweider C, doi: 10.1136/rmdopen-2014-000022, eCollection 2015, Review, PMID: 26509054
  51. Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients, PLoS One, 2015, Feb 27;10(2):e0116189, Papageorgiou A, Ziogas DC, Mavragani CP, Zintzaras E, Tzioufas AG, Moutsopoulos HM, Voulgarelis M, doi:10.1371/journal.pone.0116189, eCollection 2015, PMID: 25723713
  52. Toll-like receptor 3 stimulation promotes Ro52/TRIM21 synthesis and nuclear redistribution in salivary gland epithelial cells, partially via type I interferon pathway, Clin Exp Immunol, 2014, Dec;178(3):548-60, Kyriakidis NC, Kapsogeorgou EK, Gourzi VC, Konsta OD, Baltatzis GE, Tzioufas AG, doi: 10.1111/cei.12432, PMID: 25098814
  53. Budget Impact Analysis of Certolizumab Pegol in the Management of Patients With Moderate-To-Severe Active Rheumatoid Arthritis in Greece, Value Health, 2014, Nov;17(7):A375, Tzanetakos C, Maniadakis N, Kourlaba G, Tzioufas A, Goules A, Theodoratou T, Christou P, doi:10.1016/j.jval.2014.08.2585, Epub 2014 Oct 26, PMID: 27200816
  54. Evaluation of salivary gland protein 1 antibodies in patients with primary and secondary Sjogren's syndrome, Clin Immunol, 2014, Nov;155(1):42-6, Shen L, Kapsogeorgou EK, Yu M, Suresh L, Malyavantham K, Tzioufas AG, Ambrus JL Jr, doi: 10.1016/j.clim.2014.08.009, Epub 2014 Aug 30, PMID:25178982
  55. Imaging: diagnostic value of ultrasonography in Sjögren's syndrome, Nat Rev Rheumatol, 2014, Aug;10(8):450-2, Goules AV, Tzioufas AG, doi: 10.1038/nrrheum.2014.86. Epub 2014 Jun 3, PMID: 24890774
  56. Renal tubular acidosis in Sjögren's syndrome: a case series, Am J Nephrol, 2014, 2014;40(2):123-30, Ram R, Swarnalatha G, Dakshinamurty KV, doi: 10.1159/000365199, Epub 2014 Aug 20, PMID:25171149
  57. Outcome measures for primary Sjögren's syndrome: a comprehensive revie, J Autoimmun, 2014, Jun;51:51-6, Seror R, Theander E, Bootsma H, Bowman SJ, Tzioufas A, Gottenberg JE, Ramos-Casals M, Dörner T, Ravaud P, Mariette X, Vitali C, doi: 10.1016/j.jaut.2013.12.010, Epub 2014 Jan 8, Review, PMID: 24411404
  58. A comprehensive review of autoantibodies in primary Sjögren's syndrome: clinical phenotypes and regulatory mechanisms, J Autoimmun, 2014, Jun;51:67-74, Kyriakidis NC, Kapsogeorgou EK, Tzioufas AG, doi: 10.1016/j.jaut.2013.11.001, Epub 2013 Dec 13, Review, PMID: 24333103
  59. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome, J Autoimmun, 2014, Jun;51:89-98, Nezos A, Papageorgiou A, Fragoulis G, Ioakeimidis D, Koutsilieris M, Tzioufas AG, Moutsopoulos HM, Voulgarelis M, Mavragani CP, doi: 10.1016/j.jaut.2013.04.005, Epub 2013 Jul 9, PMID: 23845207
  60. The contribution of epigenetics in Sjögren's Syndrome, Front Genet, 2014, Apr 3;5:71, Konsta OD, Thabet Y, Le Dantec C, Brooks WH, Tzioufas AG, Pers JO, Renaudineau Y, doi: 10.3389/fgene.2014.00071. eCollection 2014, Review, PMID: 24765104
  61. Classification criteria of Sjögren's syndrome, J Autoimmun, 2014, Feb-Mar;48-49:42-5, Goules AV, Tzioufas AG, Moutsopoulos HM,            doi: 10.1016/j.jaut.2014.01.013, Epub 2014 Jan 21, Review, PMID: 24456935
  62. Differential methylation of IL8 and Tissue factor promoter in Antiphospholipid syndrome, Υποβληθείσα, 2019, Feb 2019, Patsuras MD, Karagianni P, Vlachoyiannopoulos PG
  63. Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies, Clin Rheumatol, 2019, Jan;38(1):125-132, Zampeli E, Venetsanopoulou A, Argyropoulou OD, Mavragani CP, Tektonidou MG, Vlachoyiannopoulos PG, Tzioufas AG, Skopouli FN, Moutsopoulos HM, doi: 10.1007/s10067-018-4267-z, Epub 2018 Aug 25, PMID: 30145635
  64. How can autoantibodies predict the long-term outcome of patients with interstitial lung disease? Results from a retrospective cohort study, Autoimmun Rev, 2018, Nov;17(11):1124-1133, Kampolis CF, Venetsanopoulou AI, Karakontaki F, Polychronopoulos V, Vlachoyiannopoulos P, Tzioufas AG, doi:10.1016/j.autrev.2018.06.004, Epub 2018 Sep 11
  65. Central nervous system involvement in patients with granulomatosis with polyangiitis: a single-center retrospective study, Clin Rheumatol, 2018, Mar;37(3):737-747, Fragoulis GE, Lionaki S, Venetsanopoulou A, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzioufas AG, doi: 10.1007/s10067-017-3835-y, Epub 2017 Sep 15, PMID: 28914375
  66. Mapping and predicting mortality from systemic sclerosis, Ann Rheum Dis, 2017, Nov; 76(11):1897-1905, Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, Riemekasten G, Airò P, Joven B, Vettori S, Cozzi F, Ullman S, Czirják L, Tikly M, Müller-Ladner U, Caramaschi P, Distler O, Iannone F, Ananieva LP, Hesselstrand R, Becvar R, Gabrielli A, Damjanov N, Salvador MJ, Riccieri V, Mihai C, Szücs G, Walker UA, Hunzelmann N, Martinovic D, Smith V, Müller CS, Montecucco CM, Opris D, Ingegnoli F, Vlachoyiannopoulos PG, Stamenkovic B, Rosato E, Heitmann S, Distler JHW, Zenone T, Seidel M, Vacca A, Langhe E, Novak S, Cutolo M, Mouthon L, Henes J, Chizzolini C, Mühlen CAV, Solanki K, Rednic S, Stamp L, Anic B, Santamaria VO, De Santis M, Yavuz S, Sifuentes-Giraldo WA, Chatelus E, Stork J, Laar JV, Loyo E, García de la Peña Lefebvre P, Eyerich K, Cosentino V, Alegre-Sancho JJ, Kowal-Bielecka O, Rey G, Matucci-Cerinic M, Allanore Y;
  67. Update of EULAR recommendations for the treatment of systemic sclerosis, Ann Rheum Dis, 2017, Aug;76(8):1327-1339, Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, Müller-Ladner U; EUSTAR Coauthors(International collaboration-The name of  P.G.Vlachoyiannopoulos is included in the extended author list, doi:10.1136/annrheumdis-2016-209909, Epub 2016 Nov 9
  68. Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis, Ann Rheum Dis             2016, Oct; 75(10):1743-8, Dobrota R, Maurer B, Graf N, Jordan S, Mihai C, Kowal-Bielecka O, Allanore Y, Distler O; EUSTAR coauthors, (International collaboration-The name of  P.G.Vlachoyiannopoulos is included in the extended author list), doi:10.1136/annrheumdis-2015-208024, Epub 2016 Mar 25, PMID: 27016052
  69. Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study, Arthritis Rheumatol.          2016, Oct; 68(10):2527-39, Cutolo M, Herrick AL, Distler O, Becker MO, Beltran E, Carpentier P, Ferri C, Inanç M, Vlachoyiannopoulos P, Chadha-Boreham H, Cottreel E, Pfister T, Rosenberg D, Torres JV, Smith V; CAP Study Investigators, doi: 10.1002/art.39718
  70. Digital ulcers predict a worse disease course in patients with systemic sclerosis, Ann Rheum Dis, 2016, Apr;75(4):681-6    Mihai C, Landewé R, van der Heijde D, Walker UA, Constantin PI, Gherghe AM, Ionescu R, Rednic S, Allanore Y, Avouac J, Czirják L, Hachulla E, Riemekasten G, Cozzi F, Airò P, Cutolo M, Mueller-Ladner U, Matucci-Cerinic M; EUSTAR co-authors, (International collaboration- The name of P.G.Vlachoyiannopoulos is included in the extended author list), doi:10.1136/annrheumdis-2014-205897, Epub 2015 Feb 16
  71. Elevated expression of platelet-derived chemokines in patients with antiphospholipid syndrome, J Autoimmun, 2015, Dec;65: 30-7, Patsouras MD, Sikara MP, Grika EP, Moutsopoulos HM, Tzioufas AG, Vlachoyiannopoulos PG, doi: 10.1016/j.jaut.2015.08.001. Epub 2015 Aug 15. PMID: 26283469
  72. Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population, Rheumatology (Oxford), 2015, Jul;54(7):1262-9, Hachulla E, Clerson P, Airò P, Cuomo G, Allanore Y, Caramaschi P, Rosato E, Carreira PE, Riccieri V, Sarraco M, Denton CP, Riemekasten G, Pozzi MR, Zeni S, Mihai CM, Ullman S, Distler O, Rednic S, Smith V, Walker UA, Matucci-Cerinic M, Müller-Ladner U, Launay D; EUSTAR co-workers. (International collaboration-The name of P.G.Vlachoyiannopoulos is included in the extended author list, doi:10.1093/rheumatology/keu450, Epub 2015 Jan 17, PMID: 25596413
  73. Intact calibers of retinal vessels in patients with systemic sclerosis, J Rheumatol, 2015, Apr; 42(4):608-13, Aissopou EK, Bournia VK, Protogerou AD, Panopoulos S, Papaioannou TG, Vlachoyiannopoulos PG, Matucci-Cerinic M, Sfikakis PP, doi: 10.3899/jrheum.141425, Epub 2015 Feb 1, PMID: 25641886
  74. Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study, Clin Exp Rheumatol, 2015, Mar-Apr; 33(2):216-24, Epub 2015 Feb 9, Lampropoulos CE, Orfanos P, Bournia VK, Karatsourakis T, Mavragani C, Pikazis D, Manoussakis MN, Tzioufas AG, Moutsopoulos HM, Vlachoyiannopoulos PG, PMID: 25664400
  75. Reduction of Intraepidermal Nerve Fiber Density (IENFD) in the skin biopsies of patients with fibromyalgia: a controlled study, J Neurol Sci, 2014, Dec 15;347(1-2):143-7, Kosmidis ML, Koutsogeorgopoulou L, Alexopoulos H, Mamali I, Vlachoyiannopoulos PG, Voulgarelis M, Moutsopoulos HM, Tzioufas AG, Dalakas MC, doi: 10.1016/j.jns.2014.09.035, Epub 2014 Sep 28
  76. Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: a 10-year follow-up study, Semin Arthritis Rheum, 2014, Feb; 43(4):558-65, Kampolis C, Tektonidou M, Moyssakis I, Tzelepis GE, Moutsopoulos H, Vlachoyiannopoulos PG 
  77. Incidence and prevalence of major central nervous system involvement in systemic lupus erythematosus: a 3-year prospective study of 370 patients, PLoS One, 2013, 8(2):e55843 Kampylafka EI, Alexopoulos H, Kosmidis ML, Panagiotakos DB, Vlachoyiannopoulos PG, Dalakas MC, Moutsopoulos HM, Tzioufas AG, doi:10.1371/journal.pone.0055843, Epub 2013 Feb 12
  78. Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies, Clin Rheumatol, 2019, Jan;38(1):125-132, doi: 10.1007/s10067-018-4267-z, Zampeli E, Venetsanopoulou A, Argyropoulou OD, Mavragani CP, Tektonidou MG, Vlachoyiannopoulos PG, Tzioufas AG, Skopouli FN, Moutsopoulos HM, Epub 2018 Aug 25, PubMed PMID: 30145635
  79. B cells and atherosclerosis in systemic lupus erythematosus, Expert Rev Clin Immunol, 2019, Jan 17:1-13, Koulouri V, Koutsilieris M, Mavragani CP, doi: 10.1080/1744666X.2019.1571411, [Epub ahead of print] PubMed PMID: 30652925.
  80. TNFAIP3 F127C Coding Variation in Greek Primary Sjogren's Syndrome Patients, J Immunol Res, 2018, Dec 19;2018:6923213, Nezos A, Gkioka E, Koutsilieris M, Voulgarelis M, Tzioufas AG, Mavragani CP, doi: 10.1155/2018/6923213. eCollection 2018, PubMed PMID: 30662920; PubMed Central PMCID: PMC6313987.
  81. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study, Semin Arthritis Rheum, 2018, Dec;48(3):467-474, Fanouriakis A, Adamichou C, Koutsoviti S, Panopoulos S, Staveri C, Klagou A, Tsalapaki C, Pantazi L, Konsta S, Mavragani CP, Dimopoulou D, Ntali S, Katsikas G, Boki KA, Vassilopoulos D, Konstantopoulou P, Liossis SN, Elezoglou A, Tektonidou M, Sidiropoulos P, Erden A, Sfikakis PP, Bertsias G, Boumpas DT, doi: 10.1016/j.semarthrit.2018.02.014, Epub 2018 Feb 23, PubMed PMID: 29555348
  82. Contribution of MTHFR gene variants in lupus related subclinical atherosclerosis, Clin Immunol, 2018, Aug;193:110-117, Giannelou M, Nezos A, Fragkioudaki S, Kasara D, Maselou K, Drakoulis N, Ioakeimidis D, Moutsopoulos HM, Mavragani CP, doi: 10.1016/j.clim.2018.02.014, Epub 2018 Mar 6, PubMed PMID: 29501539
  83. B-cell activating factor and related genetic variants in lupus related atherosclerosis, J Autoimmun, 2018, Aug;92:87-92, Theodorou E, Nezos A, Antypa E, Ioakeimidis D, Koutsilieris M, Tektonidou M, Moutsopoulos HM, Mavragani CP, doi:10.1016/j.jaut.2018.05.002, Epub 2018 May 31, PubMed PMID: 29859654
  84. Anxiety and Extraversion in Lupus-Related Atherosclerosis, Front Psychiatry, 2018, Jun 19;9:246, Giannelou M, Tseronis D, Antypa E, Mavragani CP, doi:10.3389/fpsyt.2018.00246, eCollection 2018, PubMed PMID: 29971022; PubMed Central, PMCID: PMC6018100
  85. Autoantibodies to ox-LDL in Sjögren's syndrome: are they atheroprotective?, Clin Exp Rheumatol, 2018, May-Jun;36 Suppl 112(3):61-67, Cinoku I, Mavragani CP, Tellis CC, Nezos A, Tselepis AD, Moutsopoulos HM, Epub 2018 Aug 13, PubMed PMID: 30156537
  86. Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjögren's syndrome, Clin Exp Rheumatol, 2018, May-Jun;36 Suppl 112(3):94-101, Kampolis CF, Fragkioudaki S, Mavragani CP, Zormpala A, Samakovli A, Moutsopoulos HM, Epub 2018 May 29, PubMed PMID: 29846161
  87. Psychological comorbidities associated with subclinical atherosclerosis in Greek patients with primary Sjögren's syndrome: a potential contribution of sleep impairment, Clin Exp Rheumatol, 2018, May-Jun;36 Suppl 112(3):68-72, Karageorgas T, Ioakeimidis D, Mavragani CP, Epub 2017 Nov 14, PubMed PMID:29148412
  88. Defective regulation of L1 endogenous retroelements in primary Sjogren's syndrome and systemic lupus erythematosus: Role of methylating enzymes, J Autoimmun, 2018, Mar;88:75-82, doi: 10.1016/j.jaut.2017.10.004, Mavragani CP, Nezos A, Sagalovskiy I, Seshan S, Kirou KA, Crow MK, Epub 2017 Oct 23, PubMed PMID: 29074164; PubMed Central PMCID: PMC5844801
  89. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report, RMD Open, 2017, Nov 14;3(2):e000507,              Bottai M, Tjärnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, García-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinka M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Wook Song Y, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, Lundberg IE; International Myositis Classification Criteria Project consortium, the Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland), doi: 10.1136/rmdopen-2017-000507, eCollection 2017, PubMed PMID: 29177080; PubMed Central PMCID: PMC5687535
  90. Antibodies against citrullinated alpha enolase peptides in primary Sjogren's syndrome Clin Immunol, 2017, Oct;183:300-303, Nezos A, Cinoku I, Mavragani CP, Moutsopoulos HM, doi: 10.1016/j.clim.2017.09.012, Epub 2017 Sep 14, PubMed PMID: 28919520
  91. MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome, Sci Rep, 2017, Aug 4;7(1):7354, Fragkioudaki S, Nezos A, Souliotis VL, Chatziandreou I, Saetta AA, Drakoulis N, Tzioufas AG, Voulgarelis M, Sfikakis PP, Koutsilieris M, Crow MK, Moutsopoulos HM, Mavragani CP, doi:10.1038/s41598-017-07347-w, PubMed PMID: 28779180; PubMed Central PMCID:PMC5544668
  92. Cardiovascular disease in systemic lupus erythematosus: A comprehensive update, 2017, J Autoimmun, 2017, Aug;82:1-12, Giannelou M, Mavragani CP, doi: 10.1016/j.jaut.2017.05.008, Epub 2017 Jun 9, Review, PubMed PMID: 28606749
  93. Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjögren's syndrome, Clin Exp Rheumatol, 2017, Jul-Aug;35(4):719-720, Quartuccio L, Mavragani CP, Nezos A, Gandolfo S, Tzioufas AG, De Vita S, Epub 2017 Mar 8, PubMed PMID: 28281461
  94. Mechanisms and New Strategies for Primary Sjögren's Syndrome, Annu Rev Med 2017, Jan 14;68:331-343, Mavragani CP, doi: 10.1146/annurev-med-043015-123313, Review, PubMed PMID: 28099084
  95. Increased frequency of the PTPN22W* variant in primary Sjogren's Syndrome: Association with low type I IFN scores, Clin Immunol, 2016, Dec;173:157-160, Vlachogiannis NI, Nezos A, Tzioufas AG, Koutsilieris M, Moutsopoulos HM, Mavragani CP, doi: 10.1016/j.clim.2016.10.015. Epub 2016 Nov 1. PubMed PMID:27810512
  96. Expression of Long Interspersed Nuclear Element 1 Retroelements and Induction of Type I Interferon in Patients With Systemic Autoimmune Disease, Arthritis Rheumatol, 2016 Nov;68(11):2686-2696, Mavragani CP, Sagalovskiy I, Guo Q, Nezos A, Kapsogeorgou EK, Lu P, Liang Zhou J, Kirou KA, Seshan SV, Moutsopoulos HM, Crow MK, doi: 10.1002/art.39795, PubMed PMID: 27338297; PubMed Central PMCID: PMC5083133
  97. Predictors of renal histopathology in antineutrophil cytoplasmic antibody associated glomerulonephritis, J Autoimmun, 2016, Aug;72:57-64, Lionaki S, Mavragani CP, Karras A, Liapis G, Somarakis G, Boletis JN, Drosos A, Tzioufas AG, Guillevin L, Moutsopoulos HM, doi: 10.1016/j.jaut.2016.05.004. Epub 2016 May 15, PubMed PMID: 27194577
  98. Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies, Scand J Immunol, 2016, Aug;84(2):100-9, Ekholm L, Vosslamber S, Tjärnlund A, de Jong TD, Betteridge Z, McHugh N, Plestilova L, Klein M, Padyukov L, Voskuyl AE, Bultink IE, Michiel Pegtel D, Mavragani CP, Crow MK, Vencovsky J, Lundberg IE, Verweij CL, doi: 10.1111/sji.12449, PubMed PMID: 27173897
  99. Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use, Medicine (Baltimore), 2016, Jun;95(25):e3766, Fragkioudaki S, Mavragani CP, Moutsopoulos HM, doi: 10.1097/MD.0000000000003766, PubMed PMID: 27336863; PubMed Central PMCID: PMC4998301
  100. Fatigue in Primary Sjögren's Syndrome: Clinical, Laboratory, Psychometric, and Biologic Associations, Arthritis Care Res (Hoboken), 2016, Jan;68(1):123-31, Karageorgas T, Fragioudaki S, Nezos A, Karaiskos D, Moutsopoulos HM, Mavragani CP, doi: 10.1002/acr.22720, PubMed PMID: 26315379
  101. Contribution of Genetic Factors to Sjögren's Syndrome and Sjögren's Syndrome Related Lymphomagenesis, J Immunol Res, 2015, 2015:754825, Nezos A, Mavragani CP, doi: 10.1155/2015/754825. Epub 2015 Oct 15. Review. PubMed PMID: 26550578; PubMed Central PMCID: PMC4624885
  102. Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis, J Autoimmun, 2015, Sep;63:47-58, Nezos A, Gravani F, Tassidou A, Kapsogeorgou EK, Voulgarelis M, Koutsilieris M, Crow MK, Mavragani CP, doi:10.1016/j.jaut.2015.07.002. Epub 2015 Jul 14. PubMed PMID: 26183766; PubMed Central PMCID: PMC4564326
  103. A BAFF receptor His159Tyr mutation in Sjögren's syndrome-related lymphoproliferation, Arthritis Rheumatol, 2015, Oct;67(10):2732-41, Papageorgiou A, Mavragani CP, Nezos A, Zintzaras E, Quartuccio L, De Vita S, Koutsilieris M, Tzioufas AG, Moutsopoulos HM, Voulgarelis M, doi: 10.1002/art.39231. PubMed PMID:26097183
  104. Clinical and laboratory predictors of distinct histopathogical features of lupus nephritis, Medicine(Baltimore), 2015, May;94(21):e829, Mavragani CP, Fragoulis GE, Somarakis G, Drosos A, Tzioufas AG, Moutsopoulos HM, doi:10.1097/MD.0000000000000829. PubMed PMID: 26020385; PubMed Central PMCID:PMC4616414
  105. Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associations.             Arthritis Res Ther, 2015, Apr 11;17:99, Gravani F, Papadaki I, Antypa E, Nezos A, Masselou K, Ioakeimidis D, Koutsilieris M, Moutsopoulos HM, Mavragani CP, doi: 10.1186/s13075-015-0613-6. PubMed PMID: 25886059; PubMed Central PMCID: PMC4416325.
  106. Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients, PLoS One, 2015, Feb 27;10(2):e0116189, Papageorgiou A, Ziogas DC, Mavragani CP, Zintzaras E, Tzioufas AG, Moutsopoulos HM, Voulgarelis M, doi: 10.1371/journal.pone.0116189. eCollection 2015. PubMed, PMID: 25723713; PubMed Central PMCID: PMC4344229.
  107. Sjögren syndrome, CMAJ, 2014, Oct 21;186(15):E579-86.  Mavragani CP, Moutsopoulos HM, doi: 10.1503/cmaj.122037, Epub 2014 Feb 24
  108. IgG4-related disease: a rheumatologist's perspective, Clin Exp Rheumatol, 2014, Sep-Oct;32(5):724-7, Soliotis F, Mavragani CP, Plastiras SC, Rontogianni D, Skopouli FN, Moutsopoulos HM, Epub 2014 Jul 28. PubMed PMID: 25068679
  109. Elevated IgG4 serum levels among primary Sjögren's syndrome patients: do they unmask underlying IgG4-related disease?, Arthritis Care Res (Hoboken), 2014, May;66(5):773-7, Mavragani CP, Fragoulis GE, Rontogianni D, Kanariou M, Moutsopoulos HM, doi: 10.1002/acr.22216. PubMed PMID: 25100215
  110. Absence of somatic MYD88 L265P mutations in patients with primary Sjogren's syndrome, Genes Immun, 2014, Jan;15(1):54-6, Voulgarelis M, Mavragani CP, Xu L, Treon SP, Moutsopoulos HM, doi: 10.1038/gene.2013.54, Epub 2013 Oct 24, PubMed, PMID: 24153350
  111. Sjögren's syndrome, Annu Rev Pathol, 2014, 2014;9:273-85, Mavragani CP, Moutsopoulos HM, doi: 10.1146/annurev-pathol-012513-104728, Epub 2013 Sep 18, Review, PubMed, PMID: 24050623
  112. Open-Label Trial of Anti-TNF-α in Dermato- and Polymyositis Treated Concomitantly with Methotrexate, European Neurology, 2008, 59:159–163, Hengstman GJ, De Bleecker JL, Feist E, Vissing J, Denton CP, Manoussakis MN, Slott Jensen H, van Engelen BG, van den Hoogen FH, doi.org/10.1159/000114036
  113. Autophagy in Myelodysplastic Syndromes: The Role of  HIF-1a/REDD1 Molecular Pathway. Blood, 2018, 132:1808   I. Stergiou, K.Kambas, S. Giannouli,  T. Katsila,  A. Dimitrakopoulou, V. Vidali, , E. Synolaki, A. Papageorgiou, , A. Nezos, G. Patrinos, P. Sideras, K. Ritis, A. Tzioufas, M. Voulgarelis, doi: https://doi.org/10.1182/blood-2018-99-112813  
  114. TNFAIP3 F127C Coding Variation in Greek Primary Sjogren's Syndrome Patients, J Immunol Res, 2018, Dec 19;2018:6923213, Nezos A, Gkioka E, Koutsilieris M, Voulgarelis M, Tzioufas AG, Mavragani CP, doi:10.1155/2018/6923213, eCollection 2018, PubMed PMID: 30662920; PubMed Central PMCID: PMC6313987
  115. Low miR200b-5p levels in minor salivary glands: a novel molecular marker predicting lymphoma development in patients with Sjögren's syndrome, Ann Rheum Dis, 2018, Aug;77(8):1200-1207, Kapsogeorgou EK, Papageorgiou A, Protogerou AD, Voulgarelis M, Tzioufas AG, doi: 10.1136/annrheumdis-2017-212639, PMID: 29779010.
  116. MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome.      Sci Rep, 2017, Aug 4;7(1):7354, Fragkioudaki S, Nezos A, Souliotis VL, Chatziandreou I, Saetta AA, Drakoulis N, Tzioufas AG, Voulgarelis M, Sfikakis PP, Koutsilieris M, Crow MK, Moutsopoulos HM, Mavragani CP, doi:10.1038/s41598-017-07347-w, PMID: 28779180; PMCID: PMC5544668
  117. A BAFF receptor His159Tyr mutation in Sjögren's syndrome-related lymphoproliferation, Arthritis Rheumatol, 2015, Oct;67(10):2732-41, Papageorgiou A, Mavragani CP, Nezos A, Zintzaras E, Quartuccio L, De Vita S, Koutsilieris M, Tzioufas AG, Moutsopoulos HM, Voulgarelis M, doi: 10.1002/art.39231. PMID:26097183.
  118. Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis, J Autoimmun, 2015, Sep; 63:47-58, Nezos A, Gravani F, Tassidou A, Kapsogeorgou EK, Voulgarelis M, Koutsilieris M, Crow MK, Mavragani CP, doi: 10.1016/j.jaut.2015.07.002, PMID: 26183766; PMC4564326
  119. Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis, J Autoimmun, 2015, Sep; 63:47-58, Nezos A, Gravani F, Tassidou A, Kapsogeorgou EK, Voulgarelis M, Koutsilieris M, Crow MK, Mavragani CP, doi: 10.1016/j.jaut.2015.07.002, PMID: 26183766; PMC4564326
  120. Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis, J Autoimmun, 2015, Sep; 63:47-58, Nezos A, Gravani F, Tassidou A, Kapsogeorgou EK, Voulgarelis M, Koutsilieris M, Crow MK, Mavragani CP, doi: 10.1016/j.jaut.2015.07.002. PMID: 26183766; PMC4564326.
  121. Clinical picture, outcome and predictive factors of lymphoma in Sjӧgren syndrome, Autoimmun Rev. 2015, 2015, Jul;14(7):641-9, Papageorgiou A, Voulgarelis M, Tzioufas AG, doi: 10.1016/j.autrev.2015.03.004, PMID: 25808075.
  122. Predicting the outcome of Sjogren's syndrome-associated non-Hodgkin's lymphoma patients, PLoS One, 2015, Feb 27;10(2): e0116189, Papageorgiou A, Ziogas DC, Mavragani CP, Zintzaras E, Tzioufas AG, Moutsopoulos HM, Voulgarelis M, doi: 10.1371/journal.pone.0116189, eCollection 2015, PMID: 25723713; PMCID: PMC4344229.
  123. A comprehensive review of myelodysplastic syndrome patients with autoimmune diseases, Expert Rev Clin Immunol, 2014, Dec;10(12):1679-88, Giannouli S, Voulgarelis M, doi: 10.1586/1744666X.2014.970181
  124. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's Syndrome, J Autoimmun, 2014, Jun; 51:89-98, Nezos A, Papageorgiou A, Fragoulis G, Ioakeimidis D, Koutsilieris M, Tzioufas AG, Moutsopoulos HM, Voulgarelis M, Mavragani CP, doi: 10.1016/j.jaut.2013.04.005, PMID: 23845207
  125. Predicting progression to lymphoma in Sjögren's syndrome patients, Expert Rev Clin Immunol, 2014, Apr;10(4):501-12, Giannouli S, Voulgarelis M, doi:10.1586/1744666X.2014.872986, PMID: 24451006
  126. Absence of somatic MYD88 L265P mutations in patients with primary Sjogren's syndrome, Genes Immun, 2014, Jan;15(1):54-6, Voulgarelis M, Mavragani CP, Xu L, Treon SP, Moutsopoulos HM, doi: 10.1038/gene.2013.54, PMID: 24153350
  127. Inheritance and Myelodysplasia progression, Leuk Res, 2013, 2013 Oct;37(10):1185-6, Giannouli S, Voulgarelis M, doi: 10.1016/j.leukres.2013.06.001, PMID: 23859717
  128. Malignant lymphoma in primary Sjögren's syndrome: an update on the pathogenesis and treatment, Semin Arthritis Rheum. 2013, Oct;43(2):178-86, Routsias JG, Goules JD, Charalampakis G, Tzima S, Papageorgiou A, Voulgarelis M, doi:10.1016/j.semarthrit.2013.04.004, PMID: 23816048
  129. Myelodysplasia and autoimmunity, Curr Opin Rheumatol, 2012, Jan;24(1):97-102, Giannouli S, Kanellopoulou T, Voulgarelis M, doi: 10.1097/BOR.0b013e32834db4ee
  130. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome, Medicine (Baltimore), 2012, Jan;91(1):1-9, Voulgarelis M, Ziakas PD, Papageorgiou A, Baimpa E, Tzioufas AG, Moutsopoulos HM, doi: 10.1097/MD.0b013e31824125e4, PubMed PMID: 22198497
  131. Myositis: Are autoantibodies pathogenic in necrotizing myopathy?, Nat Rev Rheumatol, 2018, May, 14(5): 251, Dalakas MC
  132. Necrotising autoimmune myopathy (NAM): antibodies seem to be specific markers in aiding diagnosis, J Neurol Neurosurg Psychiatry, 2016, Oct, 87:1037, Dalakas MC       
  133. Epileptic syndrome in systemic lupus erythematosus and neuronal autoantibody associations, Lupus, 2016, Oct 25 (11) 1260,          Kampylafka EI, Alexopoulos H, Fouka P, Moutsopoulos HM, Dalakas MC, Tzioufas AG
  134. Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM, BMC Neurol, 2016, Apr 16:48, Schmidt K, Kleinschnitz K, Rakocevic G, Dalakas MC, Schmidt J
  135. Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease, JNeuroimmunol, 2015, Dec 15: 289, Alexopoulos H, Kampylafka EI, Fouka P, Tatouli I, Akrivou S, Politis PK, Moutsopoulos HM, Tzioufas AG, Dalakas MC
  136. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity, J Clin Invest,     2015, Nov 125(11):4160, Quast I, Keller CW, Maurer MA, Giddens JP, Tackenberg B, Wang LX, Münz C, Nimmerjahn F, Dalakas MC, Lünemann JD
  137. Inflammatory Muscle Diseases, N Engl J Med, 2015, Jul 373(4):393, Dalakas MC
  138. Reduction of Intraepidermal Nerve Fiber Density (IENFD) in the skin biopsies of patients with fibromyalgia: a controlled study, J Neurol Sci,        2014, Dec 347(1-2):143, Kosmidis ML, Koutsogeorgopoulou L, Alexopoulos H, Mamali I, Vlachoyiannopoulos PG, Voulgarelis M, Moutsopoulos HM, Tzioufas AG, Dalakas MC
  139. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study, J Neurol Sci,        2013, Nov 334(1-2):123, Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC
  140. Incidence and prevalence of major central nervous system involvement in systemic lupus erythematosus: a 3-year prospective study of 370 patients, PloS One, 2013, 8(2):e55843, Kampylafka EI, Alexopoulos H, Kosmidis ML, Panagiotakos DB, Vlachoyiannopoulos PG, Dalakas MC, Moutsopoulos HM, Tzioufas AG